In the last two decades, many women are having their first child after the age of 35 – even age 40. Birth rates in women over the age of 35 are now the fastest growing, and the numbers of mothers aged 40-plus have nearly doubled in the last decade.
While this does somewhat dispel the dire warnings about later life fertility, older parents and parents-to-be are probably more likely to prepare for pregnancy with supplements, purchase ovulation kits to help plan conception, and potentially have more issues with fertility than younger first-time parents.
Pharmacies can support would-be parents of all age groups, but especially older couples, by providing a complete range of pharmacy services that cater for all stages of the journey, from pre-conception to birth and beyond.
What is Pregnancy Testing?
Pregnancy testing is the detection of human Chorionic Gonadotropin (hCG) in both urine and serum as early as seven to 10 days after conception, whereas, ovulation testing detects the Luteinizing Hormone (LH) level. The declining fertility rate, the emergence of highly accurate advanced technology, and the easy availability of ovulation and pregnancy monitors are expected to drive market growth. For instance, according to the statistics presented by the World Bank, India had a fertility rate of 3.311 in 2000 whereas in 2016 it declined to 2.326. However, the high costs associated with ovulation tests may hamper the growth of the market.
The demands and growth in Asia-Pacific
The Asia-Pacific pregnancy and ovulation testing market is expected to reach a market value of USD 298.68 million by 2023 from USD 209.37 million in 2017 and is expected to register a CAGR of 6.10% during the forecast period from 2018 to 2023.
In 2017, the market was led by Japan with a 23.2% share, followed by China and India with shares of 22.5% and 19.7%, respectively.
The growing demand for pregnancy testing has been observed in different parts of the world which fuels the growth of the market.
As a Market Leader in Asia-Pacific, what do you need to know?
Know the Asia-Pacific pregnancy and ovulation testing market by product type, mode of purchase, end user, and country.
Know pregnancy testing (hCG detection) and ovulation testing market.
Learn the Asia-Pacific pregnancy and ovulation testing market, by pregnancy testing (hCG detection), further segmented into urine-based testing and blood-based testing.
The Asia-Pacific pregnancy and ovulation testing market, by ovulation testing, is sub-segmented into ovulation prediction kits and fertility monitors.
The Asia-Pacific pregnancy and ovulation testing market, by mode of purchase, is segmented into non-prescription or OTC testing and prescription testing.
The Asia-Pacific pregnancy and ovulation testing market, by end user, is segmented into hospitals and clinics, fertility centers, and others.
Know pregnancy testing (hCG detection) and ovulation testing market.
Learn the Asia-Pacific pregnancy and ovulation testing market, by pregnancy testing (hCG detection), further segmented into urine-based testing and blood-based testing.
The Asia-Pacific pregnancy and ovulation testing market, by ovulation testing, is sub-segmented into ovulation prediction kits and fertility monitors.
The Asia-Pacific pregnancy and ovulation testing market, by mode of purchase, is segmented into non-prescription or OTC testing and prescription testing.
The Asia-Pacific pregnancy and ovulation testing market, by end user, is segmented into hospitals and clinics, fertility centers, and others.
Know your Key players:
SPD Swiss Precision Diagnostics GmbH
Fairhaven Health LLC
Church & Dwight Co. Inc.
Piramal Enterprises Ltd
Quidel Corporation
Mankind Pharma Ltd
TaiDoc Technology & Corporation
Cadila Healthcare Limited
Gregory Pharmaceutical Holdings Inc.
Statistics on the Market Trends:
The Asia-Pacific pregnancy and ovulation testing market is expected to reach USD 298.68 million by 2023 from USD 209.37 million in 2017 and is expected to register a CAGR of 6.10% during the forecast period from 2018 to 2023.
On the basis of product type, the pregnancy testing (hCG detection) segment is expected to account for the largest market share at a CAGR of 5.95% by 2023.
Based on mode of purchase, the non-prescription or OTC testing segment is expected to account for the largest market share at a CAGR of 6.0% by 2023.
Based on end user, the hospitals and clinics segment is expected to account for the largest market share at a CAGR of 5.78% by 2023.
Japan is expected to hold the largest share of the Asia-Pacific pregnancy and ovulation testing market at a CAGR of 23.2% by 2023.
On the basis of product type, the pregnancy testing (hCG detection) segment is expected to account for the largest market share at a CAGR of 5.95% by 2023.
Based on mode of purchase, the non-prescription or OTC testing segment is expected to account for the largest market share at a CAGR of 6.0% by 2023.
Based on end user, the hospitals and clinics segment is expected to account for the largest market share at a CAGR of 5.78% by 2023.
Japan is expected to hold the largest share of the Asia-Pacific pregnancy and ovulation testing market at a CAGR of 23.2% by 2023.
To know more on Pregnancy and Ovulation Testing Market in Asia-Pacific, visit @ https://www.aarkstore.com/ict/1097438/global-residential-security-market-by-product-forecast-2023
About Aarkstore Enterprise:
Aarkstore Enterprise is one among global marketing research companies dealing in the resale of market reports across different industries and countries. Serving thousands of clients annually with syndicated, custom market research and consulting. Clients from all sectors, including public, private, and commercial are endowed with best data modeling and processing structures with custom reports.
Related Reports: Healthcare Market Reports
Contact Details:
Aarkstore Enterprise
+91 7710006788 | contact@aarkstore.com | aarkstore.com
+91 7710006788 | contact@aarkstore.com | aarkstore.com
